Glenmark collaborates with Menarini for commercializing Ryaltris nasal spray across Europe


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Glenmark collaborates with Menarini for commercializing Ryaltris nasal spray across Europe
The licensing agreement will be effective in 33 countries throughout the European region including France, Italy, and Spain

Glenmark Pharmaceuticals Ltd., a research-led global integrated pharmaceutical company, today announced that its Swiss subsidiary, Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Menarini Group for commercializing its innovative nasal spray Ryaltris across 33 countries in Europe, including the Balkan region.

Ryaltris [olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)], developed by Glenmark, is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age.

Under the terms of the agreement, Glenmark will be responsible for the continued development and regulatory approval of Ryaltris in these markets. Menarini will be responsible for the scientific information and the commercialization of Ryaltris in those markets, following regulatory approval. Glenmark will receive an upfront payment as well as launch & sales based milestone payments from Menarini for Ryaltris sales.

“We are excited to partner with Menarini for Ryaltris across Europe as they have a proven track record in partnering and commercialising respiratory products in the region. This partnership is another step in establishing Glenmark’s respiratory focus in Europe. While Glenmark will launch Ryaltris through its own front ends in some markets, this arrangement will allow the product to compete across Europe. This is also aligned with our vision to make Ryaltris the first global brand of Glenmark by launching it in several markets across the world,” said Achin Gupta, Executive Vice President, Business Head EMEA-L (Europe, Middle East, Africa, Latam) Glenmark Pharmaceuticals.

“We are delighted to have undertaken this exclusive licensing agreement with Glenmark Pharmaceuticals. Ryaltris is a perfect addition to our European respiratory and allergy portfolio and we can count on our established experience in the relevant therapeutic area to bring this novel option to patients. We look forward to receiving Ryaltris registration and being able to launch operations as soon as practicable,” commented Pio Mei, General Manager Menarini Group.

Ryaltris (olopatadine hydrochloride and mometasone furoate) Nasal Spray, the company’s respiratory pipeline asset is partnered with Hikma Pharmaceuticals PLC for the commercialisation in the US market. Ryaltris sales continues to progress well in Australia, after the successful launch earlier this year by Glenmark’s partner, Seqirus Pty. Ltd. Ryaltris was also recently launched in South Africa. Glenmark plans to initiate commercial launch in Ukraine and Uzbekistan in the next few months. Glenmark is supporting its partner Yuhan Corporation to launch Ryaltris by the end of the March 2021 in South Korea. Glenmark has received approval for Ryaltris in Australia, South Korea, Cambodia, Ukraine, Uzbekistan, Namibia and South Africa. The company had already filed an application for Ryaltris approval in the European Union, Canada, Russia, Brazil, Malaysia, Saudi Arabia and several other markets. Glenmark’s partner in China, Grand  Pharmaceutical (China) Co. Ltd., plans to submit an IND in this financial year.

Tags : #Glenmark #LatestNewsonGlenmark23rdDec #MenariniGroup #LatestNewsonMenariniGroup23rdDec #LatestPharmaNews23rdDec #LatestPharmaCollaboration23rdDec #NasalSpray #GrandPharmaceutical #YuhanCorporation

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026